as 3201 has been researched along with Alloxan Diabetes in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujitani, B; Komiya, M; Kuromiya, A; Matsumoto, J; Murata, M; Negoro, T; Ono, Y; Suzuki, K; Ueda, S | 1 |
Bril, V; Kuromiya, A; Kurono, M; Matsumoto, T; Nakamura, K; Ono, Y | 1 |
2 other study(ies) available for as 3201 and Alloxan Diabetes
Article | Year |
---|---|
Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
Topics: Aldehyde Reductase; Animals; Crystallography, X-Ray; Diabetes Mellitus, Experimental; Enzyme Inhibitors; In Vitro Techniques; Lens, Crystalline; Male; Molecular Conformation; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Sorbitol; Spiro Compounds; Stereoisomerism; Structure-Activity Relationship; Swine | 1998 |
Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Erythrocytes; Fructose; In Vitro Techniques; Male; Neural Conduction; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve; Sorbitol; Spiro Compounds | 2009 |